Calcium Activated Nucleotidase 1/CANT1 Antibody (861206) [Alexa Fluor® 350]

• Applications: WB, ICC/IF
• Clone: 861206
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 350

Calcium Activated Nucleotidase 1/CANT1 Antibody (861206) [Alexa Fluor® 350] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Calcium Activated Nucleotidase 1/CANT1
  Gly80-Ile401
  Accession # Q8WVQ1
• Specificity: Detects human Calcium Activated Nucleotidase 1/CANT1 in ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

CANT1 (soluble Calcium-Activated NucleoTidase 1; also SCAN-1, Apyrase homolog and NF kappa B-activating protein 107) is a 45-48 kDa glycoprotein member of the apyrase (ADP/ATP hydrolysing) family of molecules. It is an ER and Golgi-embedded protein that hydrolyzes UDP in a calcium-dependent manner, and appears to be involved in the regulation of protein glycosylation and folding. It is also reported that CANT1 is essential for cell proliferation. CANT1 is not ubiquitous, but is found in multiple cell types, including prostatic epithelium, fibroblasts, lymphocytes and chondrocytes. Human CANT1 is a 401 amino acid (aa) type II transmembrane glycoprotein. It contains a 44 aa N-terminal cytoplasmic region that possesses an ER retention motif (aa 38-42), and a 339 aa luminal domain (aa 63-401). CANT1 is reported to form membrane-bound disulfide-linked homodimers, and potentially forms non-covalent homodimers in a soluble (circulating) state. The soluble form is 35‑40 kDa in size, and presumably cleaved near the transmembrane segment. However, multiple splice forms are possible, and may account for the lower MWs. Two splice forms impact the extracellular region, one which contains a four aa substitution for aa 219-401, and a second that possesses a 26 aa substitution for aa 220‑401. Two additional splice forms utilize alternative start sites at Met 31 and Met165. Over aa 80-401, human CANT1 shares 89% aa sequence identity with mouse CANT1.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.